PMID- 15597575
OWN - NLM
STAT- MEDLINE
DCOM- 20050223
LR  - 20190222
IS  - 1079-2082 (Print)
IS  - 1079-2082 (Linking)
VI  - 61
IP  - 23 Suppl 7
DP  - 2004 Dec 1
TI  - Economic considerations in the prevention and treatment of venous 
      thromboembolism.
PG  - S18-21
AB  - PURPOSE: The results of studies of the comparative efficacy, safety, feasibility, 
      and costs of using low molecular weight heparin (LMWH) or unfractionated heparin 
      (UFH) for the treatment of venous thromboembolism (VTE) are reviewed. 
      Cost-effectiveness research comparing LMWH with warfarin or UFH and comparing the 
      activated factor X inhibitor fondaparinux with LMWH for VTE prophylaxis also is 
      discussed. SUMMARY: The greater ease of administration, fewer laboratory 
      monitoring requirements, and feasibility of using LMWH safely on an outpatient 
      basis instead of on an inpatient basis facilitate earlier hospital discharge and 
      make LMWH more cost-effective than UFH for the treatment of DVT. The use of LMWH 
      instead of warfarin to prevent VTE increases costs, but it is more effective for 
      preventing DVT and death at a relatively small incremental cost per DVT event 
      avoided and cost per death averted. The total expected costs are higher, but the 
      expected cost per DVT event avoided is lower when enoxaparin is used instead of 
      UFH for VTE prophylaxis. CONCLUSION: Fondaparinux is more cost-effective than 
      enoxaparin for VTE prophylaxis, with a cost saving that increases progressively 
      over time.
FAU - Hawkins, David
AU  - Hawkins D
AD  - Mercer University School of Pharmacy, 3001 Mercer University Drive, Atlanta, GA 
      30341, USA. hawkins_dw@mercer.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Polysaccharides)
RN  - J177FOW5JL (Fondaparinux)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Fibrinolytic Agents/*economics/therapeutic use
MH  - Fondaparinux
MH  - Heparin, Low-Molecular-Weight/*economics/therapeutic use
MH  - Humans
MH  - Polysaccharides/economics/therapeutic use
MH  - Thromboembolism/drug therapy/*economics/prevention & control
MH  - Venous Thrombosis/drug therapy/*economics/prevention & control
RF  - 18
EDAT- 2004/12/16 09:00
MHDA- 2005/02/24 09:00
CRDT- 2004/12/16 09:00
PHST- 2004/12/16 09:00 [pubmed]
PHST- 2005/02/24 09:00 [medline]
PHST- 2004/12/16 09:00 [entrez]
AID - 10.1093/ajhp/61.suppl_7.S18 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2004 Dec 1;61(23 Suppl 7):S18-21. doi: 
      10.1093/ajhp/61.suppl_7.S18.